Subarachnoid hemorrhage due to aneurysm rupture has significant morbidity and mortality. For those that survive to make it to the hospital, vasospasm can contribute to long-term detrimental consequences. No definitive treatments exist that drastically reduce the inflammatory response known to be linked to vasospasm. During part 1 of my R25 funding, IL-6 modulation reduced vasospasm, prevented hydrocephalus, improved behavior, and reduced cell death. This was published in Journal of Neuroinflammation with correlation to increased IL-6 within human cerebrospinal fluid. This has now advanced to clinical trial with support from Gene Tech for pharmaceutical grade drug. This will be a first in human trial that will be the basis for the R25 part 2 funding. This will be a catalyst for further development of KOS project and advancement from Phase Oto Phase 1 and Phase 2 clinical trials. Both biomarker, behavioral, and imaging data are going to be assessed as outlined in the proposed project. This project is truly translational and is taking something from bench to bedside with significant potential impact for improving patient outcomes. Project Summary/Abstract